Maze Therapeutics Surges 6.35% on Breakthrough Trial Data and Oversubscribed Financing

Summary
• Maze Therapeutics (MAZE) surges 6.35% to $26.46, hitting a 52-week high of $27.65
• Phase 1 trial of MZE782 shows 39x phenylalanine excretion, outperforming Jnana’s JNT-57
• $150M private placement at $16.25/share fuels Phase 2 trials for PKU and CKD

Maze Therapeutics (NASDAQ: MAZE) is experiencing a historic intraday rally, driven by groundbreaking Phase 1 results for its SLC6A19 inhibitor MZE782 and a $150M capital raise. The stock’s 6.35% surge to $26.46 reflects investor confidence in its dual therapeutic potential for phenylketonuria (PKU) and chronic kidney disease (CKD), with the 52-week high of $27.65 signaling a potential breakout.

Phase 1 Trial Outperformance and Capital Infusion Ignite Momentum
Maze Therapeutics’ 6.35% intraday surge is anchored by two catalysts: (1) Phase 1 data showing MZE782’s 39x phenylalanine excretion at 960mg, surpassing Jnana Therapeutics’ JNT-57, and (2) an oversubscribed $150M private placement at $16.25/share. The trial demonstrated 42x excretion in the 240mg twice-daily cohort, validating MZE782’s mechanism to inhibit SLC6A19. This positions MAZE to compete directly with Otsuka’s $1.125B Jnana acquisition and advance Phase 2 trials for PKU and CKD in 2026.

Options Playbook: Leveraging MAZE’s Volatility with Gamma-Driven Calls
• MACD: 2.63 (above signal line 2.07), RSI: 79.06 (overbought), Bollinger Bands: $27.896 (upper), $18.936 (middle)
• Key Levels: 27.65 (52W high), 24.97 (intraday low), 17.11 (30D MA)
• Options Focus: Gamma-positive calls for short-term volatility capture

Top Option 1: MAZE20251017C25
• Code: MAZE20251017C25, Expiry: 2025-10-17, Strike: $25
• IV: 84.09% (high volatility), Delta: 0.6389 (moderate sensitivity), Gamma: 0.0660 (price-sensitive), Theta: -0.0680 (time decay), Turnover: 2,665
• Payoff: At 5% upside ($27.78), payoff = $2.78/share. High leverage (8.92%) and gamma make this ideal for a 2-week rally.

Top Option 2: MAZE20251121C25
• Code: MAZE20251121C25, Expiry: 2025-11-21, Strike: $25
• IV: 101.33% (extreme volatility), Delta: 0.6348, Gamma: 0.0351, Theta: -0.0424, Turnover: 4,900
• Payoff: At 5% upside, payoff = $2.78/share. High liquidity and IV suggest potential for volatility expansion ahead of expiry.

Action: Aggressive bulls should target MAZE20251017C25 for a 2-week breakout above $27.65. Conservative players may use MAZE20251121C25 for a longer-term play on Phase 2 trial momentum.

Backtest Maze Therapeutics Stock Performance
It looks like Maze Therapeutics (“MAZE.O”) does not have any publicly-available trading data — the data-feed returned an empty result set. Maze Therapeutics appears to be a privately held biotech company rather than an exchange-listed security, so market price history is unavailable for quantitative back-testing.Could you please confirm one of the following?1. You have a different, exchange-listed ticker in mind (e.g., perhaps a similarly named company) that you’d like analysed; or 2. You would like to perform a different kind of analysis that does not require market-price data.Once I have clarification, I can proceed with the appropriate data retrieval and back-test.

Breakout or Bubble? MAZE’s 52W High Demands Immediate Attention
Maze Therapeutics’ 6.35% surge to $26.46 reflects a confluence of Phase 1 validation and capital infusion, but the 79.06 RSI and 84.09% IV suggest overbought conditions. Investors should monitor the 27.65 52W high as a critical resistance level; a break above this could trigger a re-rating toward $30. Conversely, a pullback to the 17.11 30D MA would test conviction. Meanwhile, sector leader Amgen (AMGN) fell 2.8%, underscoring biotech sector fragility. Act now: Buy MAZE20251017C25 if $27.65 breaks, or short-term traders should watch for a 5% pullback to $25.25 for a mean reversion play.